Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to be a lentiviral vector manufacturer within CIRM's Industry Alliance Program (IAP). With $5.5 billion in funding from the state of California, CIRM is a recognized leader in the development and funding of regenerative medicine clinical trials focused on cell-based and gene therapies.
Vector BioMed helps design and manufacture high-quality pre-clinical and GMP lentiviral vectors at a speed, price, and scale that provides extraordinary value to its clients. As a preferred lentiviral vector manufacturing partner for CIRM, Vector BioMed (VBM) will assist CIRM investigators by accelerating their development to the clinic by leveraging the VBM teams' extensive experience in design and manufacture of pre-clinical and GMP-grade lentiviral vectors.
Vector BioMed assists its partners in the design of their custom lentiviral vector, helping to improve their titer and function. This leads to better therapeutic candidates with a higher probability of success once they reach the clinic. This optimization can also result in a product with a lower cost of goods, which is important for commercialization. By combining optimized vector design with Vector BioMed's proprietary and efficient manufacturing process, partners achieve a cost-effective vector supply that provides the best opportunity for success in the clinic and commercialization.
